Rangeley Capital, LLC Bicycle Therapeutics PLC Transaction History
Rangeley Capital, LLC
- $116 Billion
- Q3 2025
A detailed history of Rangeley Capital, LLC transactions in Bicycle Therapeutics PLC stock. As of the latest transaction made, Rangeley Capital, LLC holds 130,000 shares of BCYC stock, worth $842,400. This represents 0.87% of its overall portfolio holdings.
Number of Shares
130,000
Previous 75,000
73.33%
Holding current value
$842,400
Previous $521 Million
93.04%
% of portfolio
0.87%
Previous 0.62%
Shares
2 transactions
Others Institutions Holding BCYC
# of Institutions
105Shares Held
38MCall Options Held
37.6KPut Options Held
3.7K-
Baker Bros. Advisors LP New York, NY10.9MShares$70.5 Million0.69% of portfolio
-
Fcpm Iii Services B.V. Naarden, P73.45MShares$22.4 Million5.34% of portfolio
-
Armistice Capital, LLC New York, NY2.98MShares$19.3 Million0.35% of portfolio
-
Westfield Capital Management CO LP Boston, MA2.95MShares$19.1 Million0.1% of portfolio
-
Siren, L.L.C. New York, NY2.01MShares$13 Million0.61% of portfolio
About BICYCLE THERAPEUTICS plc
- Ticker BCYC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 29,676,100
- Market Cap $192M
- Description
- Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The co...